
|Videos|February 10, 2020
A 56-Year-Old Female With Recurrent Ovarian Cancer
A 56-Year-Old Female With Recurrent Ovarian Cancer
Advertisement
Case: A 56-Year-Old Female With Recurrent Ovarian Cancer
- 56-year-old female diagnosed with stage IV ovarian cancer (2016)
- Weight: 105-lb, height: 5’6”, BMI of 16.9
- Pathology: high-grade serous carcinoma, epithelial ovarian cancer
- CA-125: 475 U/mL
- CT with contrast of the pelvis, abdomen, and chest revealed a 3.5-cm mass in the right ovary and peritoneal carcinomatosis
- Patient underwent suboptimal debulking surgery; residual disease 1.5 cm
- Received IV/IP carboplatin/paclitaxel (6 cycles); achieved complete response
- 1 year later (2017) symptoms returned; CA-125, 265 U/mL; ECOG: 1
- Received carboplatin/paclitaxel (6 cycles) and bevacizumab; achieved good partial response; CA-125, 45 U/mL; continued on bevacizumab maintenance
- 8 months following second-line therapy (2018), again presented with symptoms; CA-125, 550 U/mL; ECOG: 0
- Received carboplatin/gemcitabine (6 cycles); CA-125, 54 U/mL; achieved complete response
- Currently:
- CA-125, 585 U/mL
- CT shows 2.7 cm right lower lobe lung mass
- ECOG: 0
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































